
Monthly Flea and Tick Protection that Kills Ticks* Fast1,2
Credelio® (lotilaner) is a small chewable tablet that’s tough on ticks and fleas. Credelio protects puppies and dogs against ticks, kills adult fleas, and treats and prevents flea infestations. It provides fast-acting protection that works hard all month long. Credelio is approved for puppies and dogs 8 weeks of age and older that weigh 4.4 pounds or more.
*A. americanum (lone star tick) and I. scapularis (black-legged tick)
Why Choose Credelio ™ (lotilaner)?
FastCredelio provides fast acting flea and tick protection in a small , beef flavored3 chewable tablet
- Purified
An extra purification step is taken for the active ingredient mixture, leaving only the active portion of lotilaner in the final product.4
- Gentle
Credelio is gentle enough for dogs and puppies as small as 4.4 lbs or greater and as young as 8 weeks of age.
Starts Killing Ticks* Faster†
In two head-to-head studies, lotilaner, the active ingredient in Credelio, started killing new tick* infestations faster† than sarloner in Simparica Trio® and afoxolaner in NexGard® and NexGard Plus at the end of the dosing period.1,2
*A. americanum (lone star tick) and I. scapularis (black-legged tick)
†Based on the time to statistical significance on Day 28 in two separate head-to-head studies.

The first study compared Credelio® (lotilaner) to the active ingredients in Simparica Trio® (sarolaner, moxidectin, and pyrantel) and NexGard® (afoxolaner) against Amblyomma americanum.

The second study compared Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against Ixodes scapularis.
Credelio treats and controls tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick)].
Kill Fleas Before They Can Lay Eggs
Credelio starts killing fleas in just 4 hours, with over 99% of fleas killed within 8 hours of administration. Lotilaner kills 100% of fleas 12 hours after administration and remains effective for an entire month.

In a field study with conditions favoring heavy flea challenge, two consecutive monthly treatments of dogs with lotilaner produced a 100% reduction in canine flea infestations and led to improvement in dermatologic lesion scores and owner-scored pruritus 5
In a controlled head to head study, 100% of client owned dogs were flea-free after 3 consecutive months of treatment using lotilaner, compared with 93.2% that were flea-free with afoxalaner 6
Credelio Product Information
Treatment and prevention of flea infestations and the treatment and control of tick infestations for one month in dogs and puppies 8 weeks of age and older and weighing 4.4 pounds or greater.
Prevention of Lyme disease infections as a direct result of killing black-legged ticks.
Ticks and fleas
Safe for dogs and puppies from 8 weeks of age and older and weighing 4.4 pounds or greater.
Monthly chewable
lotilaner
1 month
1, 3 and 6-count chewable tablets
Credelio Dosing Table
Credelio is available in 5 different weight classes, enabling you to offer pet owners easy dosing for dogs 4.4lbs and up.

Credelio® (lotilaner) Resources
Pet Owner Tick Check Animated Video

Tick Lifecycle Animation

Pet Owner Tick Check Video

Fleas on Dogs and the Flea Lifecycle

Puppy Rebate Tearpad
Credelio® (lotilaner) for Dogs
Find the right Credelio family product for your pets

Fast-acting tick and flea protection for dogs
Don't give ticks and fleas a fighting chance. Credelio delivers rapid, consistent tick and flea protection that lasts all month long in a small, tasty* chewable.
*U.S. field study (567 doses, 198 dogs): 80.4% from hand or bowl, 13.6% with food, 6.0% when placed in back of mouth.
Credelio
Emergency Use Authorization for Credelio (lotilaner) for New World screwworm (NWS)
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. However, Credelio is not approved for this use.
Credelio is approved for other uses.
For additional information on the EUA, please refer to the Credelio NWS Fact Sheet.
Limitations of Authorized Use
Credelio (lotilaner) is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Indications: Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) Rhipicephalus sanguineus (brown dog tick) and Haemaphysalis longicornis (longhorned tick)] for one month in dogs and puppies 8 weeks of age and older and weighing 4.4 pounds or greater. Credelio is indicated for the prevention of Borrelia burgdorferi infections (also known as Lyme disease) as a direct result of killing Ixodes scapularis vector ticks.
Important Safety Information: Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, polyuria, and diarrhea. For full prescribing information see Credelio package insert.
Credelio CAT
Emergency Use Authorization for Credelio CAT (lotilaner) for New World Screwworm (NWS)
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio CAT (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens. Credelio CAT is not approved for this use.
Credelio CAT is approved for other uses.
For additional information on the EUA, please refer to the Credelio CAT NWS Fact Sheet.
Limitations of Authorized Use
Credelio CAT (lotilaner) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio CAT (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Approved Indications
Credelio® CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) for one month in cats and kittens 8 weeks of age and older and weighing 2.0 lbs or greater.
Credelio® CAT is also indicated for treatment and control of Ixodes scapularis (black-legged tick) infestations for one month in cats and kittens 6 months of age and older and weighing 2.0 lbs or greater.
Important Safety Information
Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio® CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio® CAT against Ixodes scapularis in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, tachypnea and vomiting. For full prescribing information see the Credelio® CAT package insert.
Credelio Quattro/Credelio Quattro CA-1
Indications: Credelio Quattro is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina), hookworm (fourth stage larvae, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Borrelia burgdorferi infections (also known as Lyme disease) as a direct result of killing Ixodes scapularis vector ticks.
Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS; Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.
Important Safety Information: Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, ataxia, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult D. immitis. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.
Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. Treatment of NWS myiasis includes removal of the larvae, lesion cleaning and surgical debridement. Implement appropriate wound care and pain management.
For full prescribing information, see the Credelio Quattro/Credelio Quattro-CA1 package insert.







